A Multicenter Phase II Evaluation Of ONTAK (denileukin diftitox) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy

Trial Profile

A Multicenter Phase II Evaluation Of ONTAK (denileukin diftitox) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2005

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top